Acción EUCI EUROCINE VACCINES AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Eurocine Vaccines AB

Acciones

EUCI

SE0015382155

Precio de cierre NORDIC GROWTH MARKET
Otros sitios de cotización
 00:00:00 20/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,036 SEK +2,86 % Gráfico intradía de Eurocine Vaccines AB +4,65 % -21,74 %
30/05 Eurocine Vaccines AB (publ) informa de los resultados del tercer trimestre y nueve meses finalizados el 31 de marzo de 2024 CI
28/02 Eurocine Vaccines AB (publ) informa de los resultados del segundo trimestre y de los seis meses finalizados el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.
Correction - Eurocine Vaccines discloses interim report for July - September 2023
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023
Eurocine Vaccines discloses interim report for Juli - September 2023
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
Eurocine Vaccines discloses interim report for July 2022 - March 2023
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.
Eurocine Vaccines discloses half-year report for July - December 2022
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia
Outstanding results for Eurocine Vaccines' mRNA based HSV-2 candidate
Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción EUCI
  4. Noticias Eurocine Vaccines AB
  5. Otros idiomas